Compass Pathways Akcija

Compass Pathways ROE

Vrijednost ROE (Return on Equity) od Compass Pathways (CMPS) na dan 9. авг 2026. je 544,70 %. Prethodne godine, ROE (Return on Equity) je bio -100,28 % — promjena od -643,20% (viši).

ROE

544,70 %

YoY

-643,20%

Zadnja ažuriranja:

U godini 2026 rentabilnost sopstvenog kapitala (ROE) kompanije Compass Pathways iznosila je 544,70 %, što je porast od -643,20% u poređenju sa -100,28 % ROE prethodne godine.

Access this data via the Eulerpool API

Compass Pathways Анализа акција

Šta radi Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways je jedna od najpopularnijih kompanija na Eulerpool.

ROE у детаљу

Razjašnjenje povrata na sopstveni kapital (ROE) kompanije Compass Pathways

Povraćaj na sopstveni kapital (ROE) kompanije Compass Pathways je osnovni pokazatelj koji ocenjuje profitabilnost kompanije u odnosu na sopstveni kapital. ROE, izračunat deljenjem neto dobiti sa sopstvenim kapitalom akcionara, ilustruje efikasnost kompanije u ostvarivanju profita iz investicija akcionara. Viši ROE označava povećanu efikasnost i profitabilnost.

Poređenje iz godine u godinu

Analiza ROE kompanije Compass Pathways iz godine u godinu pomaže u praćenju trendova profitabilnosti i finansijskih performansi. Rastući ROE ukazuje na povećanu profitabilnost i stvaranje vrednosti za akcionare, dok opadajući ROE može ukazivati na probleme u stvaranju dobiti ili upravljanju sopstvenim kapitalom.

Uticaj na investicije

ROE kompanije Compass Pathways je ključan za investitore koji ocenjuju profitabilnost, efikasnost i privlačnost kompanije kao investicije. Robusni ROE ukazuje na sposobnost kompanije da pretvori investicije sopstvenog kapitala u profit, čime povećava svoju privlačnost potencijalnim i sadašnjim investitorima.

Interpretacija fluktuacija ROE

Promene u ROE kompanije Compass Pathways mogu proizaći iz fluktuacija neto dobiti, sopstvenog kapitala ili oboje. Ove fluktuacije se analiziraju sa ciljem procene efikasnosti menadžmenta, finansijskih strategija, kao i povezanih rizika i mogućnosti, te pomažu investitorima u donošenju obrazloženih odluka.

Često postavljena pitanja o akciji Compass Pathways

ROE (Return on Equity) kompanije Compass Pathways iznosi 544,70 % u 2026. godini.

ROE (Return on Equity) od Compass Pathways se promijenio sa -100,28 % na 544,70 %, što predstavlja promjenu od -643,20%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj ROE (Return on Equity) Compass Pathways od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

Dobar varira u zavisnosti od industrije i faze razvoja preduzeća. Na Eulopoolu, možete porediti ROE (Return on Equity)'s Compass Pathways sa sličnim preduzećima u sektoru i prosekom industrije da biste proverili da li je atraktivan.

Da biste proverili ROE (Return on Equity)'s, bitno je da ga uporedite sa konkurentima u istoj industriji i sektoru. Na Eulopoolu, možete pronaći direktna upoređivanja industrije za ROE (Return on Equity).

Access this data via the Eulerpool API

Профитабилност — Compass Pathways

Sve ključne metrike — Compass Pathways

Раст